Article

MellingMedical to deliver CorneaGen tissue to federal health facilities

According to the companies, the agreement will open a channel between federal health facilities and CorneaGen's laboratories.

MellingMedical and CorneaGen today announced an agreement that will expand corneal tissue options for doctors in the federal health system, including the Veterans Health Administration.

"More than 250,000 American veterans currently receive disability compensation for eye or vision conditions," Chris Melling, founder and CEO of MellingMedical noted in the statement, "We're honored to work with CorneaGen to increase the quantity and quality of corneal tissue available for treating veterans potentially suffering from sight loss or impairment due to glaucoma."

According to a news release from the companies, the agreement will open a channel between federal health facilities and CorneaGen's laboratories whose advanced tissue processing methods yield more corneas than any other corneal tissue organization in the U.S. The Seattle-based company's comprehensive portfolio of corneal transplant tissue is processed to the standards set by the FDA and the Eye Bank Association of America.

"CorneaGen provides the highest quality donor tissue, service, and products to surgeons and their patients while driving innovations in corneal care," Bernie Iliakis, president of CorneaGen said in the statement. "This partnership with MellingMedical expands our commitment to transforming the lives of those impacted by corneal disease by restoring sight, especially America's veterans."

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
(Image credit: Ophthalmology Times) ASCRS 2025: Eric D. Donnenfeld, MD, on the effect of lifitegrast clinical signs and biomarkers in dry eye disease
(Image credit: Ophthalmology Times) The Residency Report: Clinical insights from the iStent infinite trial
(Image credit: Ophthalmology Times) ASCRS 2025: Amar Shah, MD, on why hyperosmolar tear film before and after cataract surgery matters
© 2025 MJH Life Sciences

All rights reserved.